About Moleculin Biotech (NASDAQ:MBRX)
Moleculin Biotech, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of April 3, 2017, it had not generated any revenue from its operations.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MBRX
CUSIPN/A
Phone713-300-5160
Debt
Debt-to-Equity RatioN/A
Current Ratio3.76%
Quick Ratio3.76%
Price-To-Earnings
Trailing P/E Ratio-3.89
Forward P/E Ratio-3.16
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.81 per share
Price / Book2.22
Profitability
EPS (Most Recent Fiscal Year)($0.47)
Net Income$-9,800,000.00
Net MarginsN/A
Return on Equity-50.66%
Return on Assets-44.15%
Miscellaneous
Employees8
Outstanding Shares25,770,000
Moleculin Biotech (NASDAQ:MBRX) Frequently Asked Questions
What is Moleculin Biotech's stock symbol?
Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."
How were Moleculin Biotech's earnings last quarter?
Moleculin Biotech (NASDAQ:MBRX) released its earnings results on Wednesday, March, 28th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.05. View Moleculin Biotech's Earnings History.
What price target have analysts set for MBRX?
1 brokers have issued twelve-month price objectives for Moleculin Biotech's shares. Their predictions range from $8.00 to $8.00. On average, they expect Moleculin Biotech's share price to reach $8.00 in the next twelve months. View Analyst Ratings for Moleculin Biotech.
Who are some of Moleculin Biotech's key competitors?
Some companies that are related to Moleculin Biotech include Agile Therapeutics (AGRX), Aralez Pharmaceuticals (ARLZ), Flex Pharma (FLKS), Trillium Therapeutics (TRIL), BioLineRx (BLRX), Aptevo Therapeutics (APVO), KemPharm (KMPH), Medicure (MCUJF), Aileron Therapeutics (ALRN), Advaxis (ADXS), Eyenovia (EYEN), Gemphire Therapeutics (GEMP), Novelion Therapeutics (NVLN), Eleven Biotherapeutics (EBIO) and GT Biopharma (GTBP).
Has Moleculin Biotech been receiving favorable news coverage?
News headlines about MBRX stock have been trending somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Moleculin Biotech earned a news sentiment score of 0.07 on Accern's scale. They also assigned news stories about the company an impact score of 46.97 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Moleculin Biotech?
Shares of MBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Moleculin Biotech's stock price today?
One share of MBRX stock can currently be purchased for approximately $1.80.
How big of a company is Moleculin Biotech?
Moleculin Biotech has a market capitalization of $47.16 million. The company earns $-9,800,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Moleculin Biotech employs 8 workers across the globe.
How can I contact Moleculin Biotech?
Moleculin Biotech's mailing address is 2575 WEST BELLFORT SUITE 333, HOUSTON TX, 77054. The company can be reached via phone at 713-300-5160.
MarketBeat Community Rating for Moleculin Biotech (MBRX)
MarketBeat's community ratings are surveys of what our community members think about Moleculin Biotech and other stocks. Vote "Outperform" if you believe MBRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Moleculin Biotech (NASDAQ:MBRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Moleculin Biotech in the last 12 months. Their average twelve-month price target is $8.00, suggesting that the stock has a possible upside of 344.44%. The high price target for MBRX is $8.00 and the low price target for MBRX is $8.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | N/A |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $8.00 | $8.00 | $8.00 | N/A |
| Price Target Upside: | 344.44% upside | 373.37% upside | 373.37% upside | N/A |
Moleculin Biotech (NASDAQ:MBRX) Consensus Price Target History
Moleculin Biotech (NASDAQ:MBRX) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 12/20/2017 | Roth Capital | Initiated Coverage | Buy -> Buy | $8.00 | High |  |
(Data available from 4/23/2016 forward)
Moleculin Biotech (NASDAQ:MBRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Moleculin Biotech (NASDAQ MBRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 20.80%
Institutional Ownership Percentage: 3.01%
Moleculin Biotech (NASDAQ MBRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/16/2017 | Waldemar Priebe | Major Shareholder | Sell | 100,000 | $1.70 | $170,000.00 | | |
| 5/11/2017 | Walter V. Klemp | CEO | Buy | 12,000 | $0.81 | $9,720.00 | | |
| 5/5/2017 | Jacqueline Northcut | Director | Buy | 1,000 | $0.82 | $820.00 | 1,000 | |
| 4/28/2017 | Robert E George | Director | Buy | 1,000 | $0.94 | $940.00 | 1,000 | |
| 4/25/2017 | Jonathan P Foster | Insider | Buy | 10,000 | $0.86 | $8,600.00 | 10,000 | |
(Data available from 1/1/2013 forward)
Moleculin Biotech (NASDAQ MBRX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Moleculin Biotech (MBRX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 21 at 7:24 AM |
| Moleculin Biotech (MBRX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 9:01 AM |
 | Moleculin Biotech (MBRX) Reports Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial
www.streetinsider.com - April 5 at 8:58 AM |
 | Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial
finance.yahoo.com - April 4 at 5:06 PM |
| Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2017
finance.yahoo.com - March 28 at 9:46 AM |
 | Moleculin Bio adds Cleveland medical centers to U.S. Annamycin study
seekingalpha.com - March 27 at 4:21 PM |
| Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials
finance.yahoo.com - March 27 at 10:01 AM |
| Moleculin Biotech (MBRX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - March 26 at 1:29 AM |
| Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery
finance.yahoo.com - March 20 at 9:45 AM |
| Moleculin to Present at the 30th Annual ROTH Conference Tuesday, March 13, 2018
finance.yahoo.com - March 6 at 9:23 AM |
 | The Market In 5 Minutes: Trump, Tariffs, Trade Wars And More
feeds.benzinga.com - March 2 at 10:38 AM |
| Exclusive: Moleculin CEO Says Acute Myeloid Leukemia Candidate Could Be 'Remarkable'
www.benzinga.com - March 2 at 9:24 AM |
| Reminder: Moleculin Announces Conference Call to Discuss Recent Discovery of New Molecule and Business Update on Wednesday, February 28, 2018
finance.yahoo.com - February 28 at 4:57 PM |
| Moleculin Announces Conference Call to Discuss Recent Discovery of New Molecule and Business Update on Wednesday, February 28, 2018
finance.yahoo.com - February 22 at 9:19 AM |
| Moleculin Biotech (MBRX) Prices $9 Million Registered Direct Offering
www.streetinsider.com - February 17 at 9:02 AM |
| Here’s Why Moleculin Biotech Inc (MBRX) is Down Big Today
finance.yahoo.com - February 16 at 4:33 PM |
| Moleculin Biotech's Volatility, Explained
feeds.benzinga.com - February 16 at 2:31 PM |
| Moleculin Announces Pricing of $9 Million Registered Direct Offering
finance.yahoo.com - February 16 at 9:10 AM |
 | Moleculin Biotech Explodes on Breakthrough Cancer Treatment
www.msn.com - February 15 at 4:33 PM |
| Moleculin Biotech (MBRX) Reports Breakthrough Discovery of New Molecule for Cancer Treatment
www.streetinsider.com - February 15 at 4:33 PM |
| Moleculin Biotech's stock rockets after 'major breakthrough' in cancer treatment
finance.yahoo.com - February 15 at 4:33 PM |
| Moleculin Announces Breakthrough Discovery of a New Molecule for Cancer Treatment
finance.yahoo.com - February 15 at 8:47 AM |
 | Biotech and Big Pharma Industry Increase R&D Activity for Novel Cancer Therapies
www.prnewswire.com - February 13 at 9:06 AM |
| Moleculin Announces Collaboration with Emory University to Develop Novel Treatment of Pediatric Brain Cancer
finance.yahoo.com - February 13 at 9:06 AM |
| Novel and Complex Cancer Drug Developments Reshaping Pharma Industry
www.prnewswire.com - February 7 at 9:10 AM |
| Moleculin Announces Activity with Pancreatic Cancer Drug
finance.yahoo.com - February 7 at 9:10 AM |
| Moleculin Biotech (MBRX) Upgraded at ValuEngine
www.americanbankingnews.com - February 4 at 10:48 PM |
| Leading Leukemia Experts Join Moleculin's Science Advisory Board
finance.yahoo.com - January 17 at 9:01 AM |
| Moleculin Biotech (MBRX) Announces Development Pipeline Expansion with Immuno-Stimulating STAT3 Inhibitor
www.streetinsider.com - January 11 at 9:29 AM |
| Moleculin Expands Leukemia Development Portfolio with Immuno-Stimulating STAT3 Inhibitor
finance.yahoo.com - January 10 at 9:17 AM |
| Moleculin Biotech (MBRX) Reports Polish Approval for Leukemia Clinical Trial
www.streetinsider.com - December 23 at 6:08 AM |
| Moleculin Biotech (MBRX) Reports Polish Approval for Leukemia ... - StreetInsider.com
www.streetinsider.com - December 22 at 9:21 AM |
| Moleculin Announces Polish Approval for Leukemia Clinical Trial
finance.yahoo.com - December 21 at 9:11 AM |
| Moleculin Biotech (MBRX) Receives New Coverage from Analysts at Roth Capital
www.americanbankingnews.com - December 20 at 10:40 AM |
| Moleculin Biotech (MBRX) Secures $2M Private Grant for WP1066 Drug
www.streetinsider.com - December 7 at 9:15 AM |
| Moleculin's WP1066 Drug receives $2 million Private Grant
finance.yahoo.com - December 6 at 5:37 PM |
| Mid-Afternoon Market Update: Francesca's Drops On Earnings Miss; Revance Therapeutics Shares Gain - Benzinga
www.benzinga.com - December 5 at 5:31 PM |
| Mid-Day Market Update: Barnes & Noble Education Surges After Q2 Results; Ascena Retail Shares Slide - Benzinga
www.benzinga.com - December 5 at 5:31 PM |
| Moleculin's WP1066 Drug gets FDA Brain Tumor IND Clearance
finance.yahoo.com - December 5 at 9:52 AM |
| Why Moleculin Biotech Inc’s (MBRX) Ownership Structure Is Important
finance.yahoo.com - November 28 at 5:34 PM |
| Moleculin to Present at the 10th Annual LD Micro Main Event on December 5, 2017 at 11:30 a.m. PT
finance.yahoo.com - November 22 at 2:53 AM |
| Moleculin Biotech, Inc. (MBRX) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 15 at 1:13 PM |
| Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017
finance.yahoo.com - November 15 at 6:12 AM |
| Moleculin Biotech, Inc. (MBRX) Set to Announce Earnings on Monday
www.americanbankingnews.com - November 13 at 2:08 AM |
| Moleculin Appoints Dr. Sandra Silberman as Chief Medical Officer -- New Products
finance.yahoo.com - November 8 at 4:56 PM |
| Moleculin Announces MD Anderson has Filed an IND with the FDA on its Drug WP1066 for the Treatment of Brain Tumors
finance.yahoo.com - November 2 at 6:14 AM |
| Moleculin Requests Authorization from the Polish Government to Advance Annamycin
finance.yahoo.com - October 25 at 7:01 AM |
| Moleculin Requests Authorization from the Polish Government to Advance Annamycin
finance.yahoo.com - October 25 at 7:01 AM |
| Moleculin Announces 14 Qualified Clinical Sites Requesting Participation in Annamycin Trial
finance.yahoo.com - October 19 at 6:08 AM |
| Moleculin Announces Strategic Collaboration to Develop Immune Stimulation Drug
finance.yahoo.com - October 11 at 3:19 PM |
Moleculin Biotech (NASDAQ:MBRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Moleculin Biotech (NASDAQ:MBRX) Income Statement, Balance Sheet and Cash Flow Statement
Moleculin Biotech (NASDAQ MBRX) Stock Chart for Monday, April, 23, 2018
Loading chart…
